Antibodies and their multivalent constructs for cancer therapy

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Cancer remains a significant global health threat, with increasing incidence and mortality rates.
• The anti-cancer drug industry has expanded significantly since the mid-20th century.
• Monoclonal antibodies (mAbs) represent a key advancement in cancer therapeutics.

Purpose of the Study:

• To review currently FDA-approved monoclonal antibodies for cancer treatment.
• To discuss emerging antibody platforms in clinical research and development.
• To highlight advancements in antibody engineering for improved anti-cancer efficacy.

Main Methods:

• Review of FDA-approved monoclonal antibodies for cancer therapy.
• Analysis of antibody platforms in the research and clinical pipeline.
• Discussion of engineering techniques enhancing antibody tumor penetration, binding, and efficacy.

Main Results:

• Twelve monoclonal antibodies have been approved by the FDA for cancer treatment.
• Recombinant and engineering techniques have driven significant gains in antibody-based cancer therapy efficacy.
• New antibody platforms are being developed for superior tumor targeting and therapeutic effect.

Conclusions:

• Monoclonal antibodies are a vital and growing component of modern cancer treatment.
• Ongoing research and engineering innovations promise further improvements in antibody-based cancer therapies.
• Advanced antibody platforms offer potential for enhanced tumor penetration, binding, and overall clinical efficacy.